SUMMARY Of 29 524 hospitalised medical patients monitored in a drug surveillance programme 1835 (6 2 %) received the xanthine oxidase inhibitor allopurinol. After the exclusion of skin reactions adverse effects were attributed to this drug in 33 (1.8 %) patients, the most frequent being haematological abnormalities (11 patients, 0 6 %) and diarrhoea and drug fever (5 each, 0 3 %). Adverse effects were dose-related. Reactions were unrelated to age, weight, reason for therapy, admission blood urea, or albumin concentrations. Acute exacerbation of gout was troublesome in 3 patients (1 in 600 exposed).
attending physician. When an adverse effect is reported, details of the effect are recorded on a separate form and the reaction is evaluated by a trained clinical pharmacologist.
This report is derived from data gathered since 1966 on 29 524 patients in 22 hospitals, of whom 1835 (6 2 %) received allopurinol.
Allopurinol is frequently administered with other potent drugs (for example, antitumour agents and antibiotics) which cause many adverse effects. It is therefore often difficult to ascribe a particular reaction to this drug with complete confidence. This problem is particularly troublesome with skin rashes. Several publications from this programme have reviewed different aspects of allergic skin reactions in allopurinol recipients.78 In the light of these reviews it appears that in almost all cases skin rashes in recipients of group.bmj.com on April 20, 2017 -Published by http://ard.bmj.com/ Downloaded from Acute adverse reactions attributed to allopurinol in hospitalised patients 247
Of the 11 patients with haematological reactions attributed to allopurinol 6 developed leucopenia and/or thrombocytopenia. Brief details of 3 of these patients are given in Table 2 (cases 3, 4 and 5). The remaining patients with leucopenia (1) and thrombocytopenia (2) had reductions of peripheral cell counts which were not severe and did not result in any clinical complications. All 3 recovered on withdrawing therapy.
Three patients developed excessive anticoagulation when taking warfarin and allopurinol, the time relationships being such as to render a drug interaction possible. In 1 (case 7, Table 2 ) extensive intrapulmonary haemorrhage developed while he was anticoagulated excessively (prothrombin time 71 s).
Hepatotoxicity was reported in 3 patients. A 61 year-old-male with cardiac failure (case 2, Table   2 ) developed jaundice and hepatocellular necrosis after 5 days' treatment with allopurinol (300 mg daily). Coincidental therapy for chest infection included erythromycin 8 g in the preceding week. The attending physician attributed hepatitis to allopurinol and not to erythromycin. No biopsy was taken, and the patient recovered on stopping both drugs. A 19-year-old male with histiocytosis X developed jaundice and hepatocellular necrosis (bilirubin 14-5 mg/100 ml (248 ,umol/l), alanine transferase 355 U/l), after receiving allopurinol 200 mg daily for 19 days. The patient gradually improved despite continuing allopurinol, which was doubtfully incriminated as a cause of the liver disorder by the attending physician. Finally, a 75-year-old male with pancytopenia developed jaundice (bilirubin 4.0 mg/100 ml (68 ,umol/l)) of hepatocellular type (alanine transferase 413 U/l) after 16 days of 300 mg allopurinol daily. Jaundice regressed after cessation of allopurinol therapy. No other potential hepatotoxin was given. The cause of underlying pancytopenia was not fully established. Although allopurinol was incriminated in all 3 cases with varying degrees of conviction, and although jaundice regressed on stopping the drug, no objective evidence proving the association can be provided, and the link between drug and disorder must be regarded as tenuous.
Overall allopurinol toxicity was unrelated to coadministration of digoxin, thiazide diuretics, and cytotoxic drugs other than mercaptopurine. Only 21 patients received both allopurinol and mercaptopurine during their admission to hospital, and of these 2 (9 6%) developed reactions attributed to allopurinol as compared to 31 of 1814 patients who received allopurinol alone (1 8 %) (X2 = 7X18, P<0-01). In none of these cases was the reaction of major severity.
Acute flare-up of gout was reported in 3 patients. All were males suffering from primary or druginduced gout, and were asymptomatic when treatment with allopurinol 300 mg daily was started. Within 2-4 days of starting therapy each developed acyte symptoms of gout, which responded to colchicine (2 patients) or phenylbutazone (1 patient). Thereafter all 3 continued allopurinol treatment without difficulty.
Discussion
Clinical experience with allopurinol suggests that most patients tolerate this drug well5 9-a finding strongly supported by our data. Undesired or unintended effects of therapy were reported in only 1-8% of 1835 consecutive recipients.
Severe hypersensitivity reactions have been attributed to allopurinol. The range of lesions includes widespread skin lesions varying from single erythematosus eruptions to vasculitic lesions, toxic epidermal necrolysis, fever, eosinophilia, nephritis, and hepatitis.10-4 The mechanism whereby allopurinol may cause such effects is not understood. Symptoms may arise within days of beginning allopurinol but in some cases are delayed by 1 or more months.10 In the present series 2 patients developed possible hypersensitivity reactions to allopurinol (both of life-threatening severity; cases 2 and 6). In both the reaction developed rapidly after starting allopurinol. Both had diuretic-related hyperuricaemia, a condition thought to predispose to allopurinol hypersensitivity. 13 Allopurinol is metabolised to oxipurinol, which is excreted slowly by the kidney.15 16 This metabolite is retained in renal impairment and it has been suggested that adverse effects of allopurinol are more frequent when there is renal insufficiency. This was not the case in the present series, which indicates either that the toxicity of oxipurinol is minimal or that the reduction in dosage normally made in patients with renal failure is effective in minimising toxicity.
Leucopenia and/or thrombocytopenia were infrequently attributed to allopurinol therapy in this series. Although they were not confined to patients taking cytotoxic drugs, in general, severe bone marrow depression was reported only in those recipients of allopurinol with underlying tumours who also received cytotoxic therapy. Under those circumstances it is impossible to isolate the effect of allopurinol from that of the cytotoxic drugs or the underlying disease. However, the mode of action of allopurinol indicates that it will reduce the metabolic clearance of both mercaptopurine and azathioprine and hence lead to a prolongation of the effect of unit doses of either.17 While this may account for some of the cases of bone marrow depression reported here, it does not explain them all. In particular it does not explain the reported interaction between allopurinol and cyclophosphamide resulting in bone marrow damage,18 nor does it account for the occasional instances of mild leucopenia or thrombocytopenia occurring in patients with no malignancy. It appears likely that allopurinol itself may rarely cause mild transient leucopenia or thrombocytopenia, which is reported only if the patients develop a serious consequence of the reaction such as major infection (case 3, Table 2 ).
Reversible hepatotoxicity has been reported in recipients of allopurinol, usually as part of a generalised hypersensitivity reaction.10 This appears to be infrequent and has been observed in 3 of 1835 consecutive recipients in the present study (i.e., 1 per 600 exposed In the current series this occurred in only 3 patients (1 in 600). However, it should be emphasised that hospitalised medical patients represent a selected population. Cancer sufferers figured prominently among the recipients of allopurinol, which was usually prescribed prophylactically. Only 19 % of those studied received the drug for the treatment of gout, the major indication fr its use in the general community. All 3 patients who developed acute gout were in the latter category, suggesting a prevalence of this reaction in gouty subjects of 1 in 120 exposures.
The present study of a large series of recipients of allopurinol indicates that therapy with this drug is seldom associated with toxicity, though when it does arise it may be of serious consequence, particularly in patients with underlying malignancy. Apart from skin reactions the principal adverse effects are haematological reactions, diarrhoea, and fever. 
